Imaging Axonal Degeneration and Repair in Preclinical Animal Models of Multiple Sclerosis by Soumya S. Yandamuri & Thomas E. Lane
May 2016 | Volume 7 | Article 1891
Review
published: 19 May 2016
doi: 10.3389/fimmu.2016.00189










Thomas E. Lane  
tom.lane@path.utah.edu
Specialty section: 
This article was submitted 
to Inflammation, 






Yandamuri SS and Lane TE (2016) 
Imaging Axonal Degeneration and 
Repair in Preclinical Animal 
Models of Multiple Sclerosis. 
Front. Immunol. 7:189. 
doi: 10.3389/fimmu.2016.00189
imaging Axonal Degeneration and 
Repair in Preclinical Animal Models 
of Multiple Sclerosis
Soumya S. Yandamuri1 and Thomas E. Lane1,2*
1Department of Bioengineering, University of Utah, Salt Lake City, UT, USA, 2Department of Pathology, School of Medicine, 
University of Utah, Salt Lake City, UT, USA
Multiple sclerosis (MS) is a central nervous system (CNS) disease characterized by 
chronic neuroinflammation, demyelination, and axonal damage. Infiltration of activated 
lymphocytes and myeloid cells are thought to be primarily responsible for white matter 
damage and axonopathy. Over time, this neurologic damage manifests clinically as 
debilitating motor and cognitive symptoms. Existing MS therapies focus on symptom 
relief and delay of disease progression through reduction of neuroinflammation. However, 
long-term strategies to remyelinate, protect, or regenerate axons have remained elusive, 
posing a challenge to treating progressive forms of MS. Preclinical mouse models and 
techniques, such as immunohistochemistry, flow cytometry, and genomic and pro-
teomic analysis have provided advances in our understanding of discrete time-points of 
pathology following disease induction. More recently, in vivo and in situ two-photon (2P) 
microscopy has made it possible to visualize continuous real-time cellular behavior and 
structural changes occurring within the CNS during neuropathology. Research utilizing 2P 
imaging to study axonopathy in neuroinflammatory demyelinating disease has focused 
on five areas: (1) axonal morphologic changes, (2) organelle transport and health, (3) 
relationship to inflammation, (4) neuronal excitotoxicity, and (5) regenerative therapies. 
2P imaging may also be used to identify novel therapeutic targets via identification and 
clarification of dynamic cellular and molecular mechanisms of axonal regeneration and 
remyelination. Here, we review tools that have made 2P accessible for imaging neuro-
pathologies and advances in our understanding of axonal degeneration and repair in 
preclinical models of demyelinating diseases.
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Abbreviations: 2d2, MOG peptide 35–55 TCR transgenic; APP, amyloid precursor protein; ATP, adenosine triphosphate; 
CerTN-L15, troponin C expressing Ca2+ sensing transgenic animal; CFP, cyan fluorescent protein; EAE, experimental autoim-
mune/allergic encephalomyelitis; EB3, end-binding protein 3; FAD, focal axonal degeneration; FRET, Förster resonance energy 
transfer; GECI, genetically encoded Ca2+ indicator; GFP, green fluorescent protein; JHMV, John Howard Mueller strain of 
murine hepatitis virus; LFB, Luxol fast blue; MHC, major histocompatibility complex; MOG, myelin oligodendrocyte glyco-
protein; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; MS, multiple sclerosis; NAWM, normal 
appearing white matter; NPC, neural precursor cell; OT-2, ovalbumin peptide 323–339 TCR transgenic-binding MHC Class 
II; PLP, proteolipid protein (promoter for mature oligodendrocytes); RAG, recombination activating-gene; RFP, red fluorescent 
protein; RNS, reactive nitrogen species; ROS, reactive oxygen species; SMI31, Sternberger monoclonal incorporated monoclo-
nal antibody 31; SMI32, Sternberger monoclonal incorporated monoclonal antibody 32; TCR, T-cell receptor; Thy1, thymocyte 
antigen 1 (promoter for neuron subset); TMEV, Theiler’s murine encephalomyelitis virus; TN-XXL, troponin C expressing 
Ca2+ sensing transgenic animal; XFP, “X” fluorescent protein (any spectral variant of GFP); YFP, yellow fluorescent protein.
FiGURe 1 | (A) The outside-in model of axonal degeneration predicts that 
demyelination occurs before axonopathy due to myelin-degenerative factors 
released by inflammatory cells (M = macrophages/microglia, T = T 
lymphocytes) within the CNS. The loss in protection and trophic support by 
myelin results in axonal damage in this model. (B) The inside-out model of 
axonal degeneration or Wallerian degeneration predicts that axonopathy 
occurs before demyelination due to neurotoxic factors released by 
inflammatory cells within the CNS. These factors may diffuse through myelin 
or pass through the nodes of Ranvier.
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iNTRODUCTiON
Multiple sclerosis (MS) is a neuroinflammatory demyelinating 
disease affecting over 2.3 million individuals worldwide (1). 
Macrophages and T lymphocytes infiltrate the central nerv-
ous system (CNS), and along with resident microglia, release 
proinflammatory cytokines, culminating in oligodendrocyte 
damage and death (2). The resulting multifocal white matter 
demyelinating lesions cause dampening of saltatory signal 
transduction in axons (2–5). This ultimately leads to a variety 
of insidious clinical symptoms, including motor, cognitive, 
and behavioral deficiencies, such as numbness or pain in 
extremities, loss of vision, and dementia. These symptoms may 
manifest as episodes separated by functional recovery, termed 
relapsing-remitting MS, or may continue to progress with 
increasing debilities, termed progressive MS (6). It is believed 
that remyelination, reduced neuroinflammation, and adaptive 
CNS responses are responsible for remitting phases of disease 
(7–10). Therefore, in an attempt to prolong remission and pre-
vent new lesion formation, disease-modifying therapies focus 
on reducing leukocyte trafficking or proliferation in the CNS. 
However, these FDA-approved therapeutics have only been 
indicated for relapsing-remitting MS. With 15% of MS patients 
diagnosed with progressive MS at onset (termed primary-
progressive MS) and 80% of patients developing progressive 
MS within 20  years of diagnosis (secondary progressive), 
treatments for progressive MS have been long sought after yet 
remain elusive (11).
The historical focus on neuroinflammation and demyelination 
in MS may have delayed the development of effective treatments 
for progressive MS. Irreversible axonal damage and neurode-
generation have been identified as causative factors for chronic 
functional disability and progressive disease (11, 12). Indeed, 
patients with progressive forms of MS have increasing CNS atro-
phy in the spinal cord, cerebellum, and cerebral cortex, attributed 
to axonal loss (13–15). Progressive patients are also more likely 
to have decreased levels of N-acetyl aspartate within the brain, 
indicating a precipitous drop in neurons and corresponding evi-
dence has shown an increase in neuronal apoptosis (12, 16, 17). 
Morphological indicators of axonal pathologies, such as ovoids, 
swelling, thinning, and transection are found in CNS biopsies 
of MS patients and are also evident in other neurodegenerative 
diseases (17, 18). Furthermore, internal structural changes have 
been found by immunohistochemistry. SMI32 is a monoclonal 
antibody that recognizes non-phosphorylated neurofilament, 
which is found in damaged axons. Accumulation of amyloid 
precursor protein (APP) is found in damaged axons due to 
transport deficiencies. Both SMI32 and APP positive axons have 
been found in demyelinating lesions in post-mortem MS biopsies 
(17–19). Importantly, the loss in neurons in progressive MS is 
attributed to axonal degeneration (20).
Causation of MS axonopathy has been contested. 
Inflammatory demyelinating lesions can be identified in patients 
by magnetic resonance imaging (MRI) or in post-mortem CNS 
biopsies by Luxol fast blue (LFB) staining. Historically, axonal 
loss has been considered a result of demyelination. This is the 
“outside-in-model” of axonal degeneration in demyelinating 
disease (Figure  1A). More recently, axon loss has also been 
found in non-lesional white matter of post-mortem MS biopsies, 
as identified by MRI or LFB, termed “normal appearing white 
matter” (NAWM) and indicating axonal damage in the absence 
of inflammation and demyelination (21). This form of axon dam-
age is referred to as Wallerian degeneration or the “inside-out-
model” of axon degeneration, where the myelin sheath has the 
appearance of an empty tube, due to axon loss within the myelin 
sheath (Figure 1B). The relative importance of these two models 
is significant in understanding optimal treatment strategies: 
should axon and neurodegeneration be targeted for treatment 
or is prevention of demyelination sufficient to save axons and 
neurons?
Many factors contribute to axonal degeneration, complicating 
our ability to confirm whether demyelination or axonopathy 
occurs first. The lack of physical and trophic support from the 
myelin sheath may contribute to axonal loss (22, 23). However, 
axonal damage is not always secondary to demyelination. 
Axonopathy has also been attributed to attack by inflammatory 
cells and their secretion of inflammatory cytokines and toxic spe-
cies (22–25). Increased macrophage and microglia density within 
the CNS microenvironment have been attributed to axonal loss 
(17, 24). Further investigation showed that microglia contact 
and surround axons and dendrites in cortical lesions (17). Some 
microglia encapsulate the transected ends of axons in white mat-
ter lesions, implying a direct involvement in degenerating axons. 
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In addition, CD8+ T cell density is also correlative with axonal 
damage in MS patient biopsies (24).
Myeloid cells may also cause axonal damage by releasing 
neurodegenerative molecules, such as glutamate, reactive oxy-
gen species (ROS), and reactive nitrogen species (RNS) (26–28). 
Furthermore, astrocytes and oligodendrocytes have decreased 
expression of glutamate clearance and metabolism receptors in 
MS lesions (28–30). As a result, increased glutamate has been 
detected in the cerebrospinal fluid of MS patients and within 
tumefactive demyelinating lesions (31, 32). An increase in 
glutamate receptors on neurons increases their vulnerability 
to excitotoxicity and degeneration (28–30). ROS, RNS, and 
glutamate may also traverse the myelin sheath by diffusion 
or through the nodes of Ranvier, degenerating the axon, and 
highlighting one possible cause of Wallerian degeneration in 
myelinated axons (33–35).
Activation of neuronal glutamate receptors by glutamate 
and RNS upregulates extracellular ROS and RNS release and 
intracellular [Ca2+] (36–39). Increased intracellular [Ca2+] 
activates neurofilament fragmenting proteases, which may 
cause the transport deficiencies seen in degenerated axons (40). 
Intracellular [Na+] also increases due to an increase in axonal 
Na+ channels, a neuronal adaptive response to demyelination, 
and due to increased import of Na+ by Na+/Ca2+ exchangers 
that expel excess intracellular Ca2+ (33, 41, 42). As a result, Na+/
K+-ATPase activity rises to expel excess Na+, causing depletion 
of ATP (43–48). Energy deficiencies are exacerbated by mito-
chondrial functional impairment caused by ROS and RNS, as 
well as insufficient mitochondria along the length of the axon 
due to the previously mentioned axonal transport deficiencies 
(43–48). Therefore, ROS, RNS, and glutamate cause impairment 
of neurofilament integrity, mitochondria density and func-
tion, energy metabolism, and ATP synthesis in axons (28, 31, 
49–52). As is the case in any biological system, a large number of 
factors play a role in axonal degeneration, with varied relation-
ships, feedback loops, and redundancies: inflammation causes 
demyelination, demyelination causes axonopathy, inflammation 
causes axonopathy, and demyelination enhances inflammation. 
These interconnected relationships increase the difficulty of 
finding a single therapeutic target for progressive MS.
Histopathology, confocal imaging, and molecular biology 
techniques have yielded insight into some of these relationships; 
however, a definitive understanding of axonal degeneration in 
MS is still lacking. The mechanisms that result in neurodegenera-
tion are both complex and dynamic, with axon damage caused 
by inflammatory cell attack, inflammatory cytokines, excitotoxic 
molecules, and myelin damage (22–25). This process also 
involves flux in molecular and ion concentrations, morphologic 
changes, internal structure and organelle damage, and electrical 
conductivity dysfunction. The highly dynamic and multi-variate 
nature of axonal degeneration makes it a well-suited beneficiary 
of real-time imaging. In the last half-decade, the convergence 
of 2P microscopy, preclinical murine MS models, and various 
transgenic animals and dyes have allowed for real-time visualiza-
tion of axonal degeneration with respect to morphologic changes, 
organelle transport and damage, inflammation and axon health, 
neuronal excitotoxicity, and regenerative therapeutics.
THe TOOLS
Preclinical Animal Models of MS
Thus far, 2P microscopy has been used to study axonal degenera-
tion following infection of mice with the neurotropic JHM strain 
of mouse hepatitis virus (JHMV) or induction of experimental 
autoimmune encephalomyelitis (EAE) (53–57). While these 
models are independent and unique from one another, they 
both share important histologic features with MS, including 
neuroinflammation, demyelination, and neurodegeneration. 
EAE is the most commonly used preclinical murine model of 
MS. By the mid-1900s, researchers discovered that injection 
of emulsified CNS tissue or transfer of lymph node cells from 
animals sensitized with CNS tissue induced encephalomyelitis in 
a variety of animal hosts (58–61). Today, “active” EAE is initiated 
by injection of defined encephalitogenic myelin protein epitopes 
in combination with complete Freund’s adjuvant (CFA), whereas 
“passive” EAE is induced by transfer of encephalitogenic myelin-
sensitized T lymphocytes (60, 62–69). Some of these EAE models 
also require administration of the microbial-based immunologic 
adjuvant pertussis toxin (PT), which is thought to enhance EAE 
induction by increasing blood–brain barrier (BBB) permeability, 
expanding myeloid cells and antigen-specific T lymphocytes, 
reducing regulatory T lymphocytes, and modulating expression 
of inflammatory cytokines (70–72). PT is often administered in 
donor mice for passive EAE and in active EAE mice, depending 
on the murine strain and immunizing antigen (73). Like in MS, 
the EAE clinical course can be highly variable; researchers can 
achieve an intended MS-like clinical course based on murine 
strain, injected antigen, and adjuvant (74).
All active EAE 2P studies of axonopathy have been induced 
by injection of C57BL/6 mice with myelin oligodendrocyte 
glycoprotein (MOG) peptide fragment 35–55 (MOG35–55) in 
conjunction with CFA, stimulating a robust T cell response. In 
these studies, PT is injected on days 0 and 2 post-immunization, 
resulting in neuroinflammation and disease induction. Axonal 
density in MOG35–55 immunized C57BL/6 mice is significantly 
decreased in lesions, NAWM, and gray matter by disease onset, 
when measured by Bielschowsky Silver impregnation (75). 
SMI32 and APP positive axons are found prior to disease onset 
and demyelination (76). Interestingly, T cell infiltration is very 
low at this point; rather, astrocyte hypertrophy is widely observed 
concomitant with axon injury (76). These data demonstrate that 
axonal damage may precede detectable demyelination in EAE.
A number of viral pathogens have been implicated in human 
MS, including Epstein–Barr virus (EBV) and human herpesvi-
rus-6 (HHV-6) (77, 78). The differential prevalence of MS by 
geographic location and the increased risk to individuals who 
relocate to high prevalence geographies may be attributed to a 
viral infection (79). Therefore, preclinical viral models of MS 
are important tools for understanding disease pathogenesis and 
testing potential therapeutic mechanisms. JHMV is a positive-
sense single-stranded RNA virus of the Coronaviridae family. 
Intracranial injection of JHMV into C57BL/6 mice results in 
acute encephalomyelitis and chronic inflammatory demyelina-
tion and axonopathy in the CNS (80). While JHMV infects and 
replicates within oligodendrocytes, astrocytes, and microglia, 
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demyelination occurs due to T lymphocyte-directed responses 
against viral antigens and macrophage-mediated stripping of 
myelin, and not virus-induced apoptosis/necrosis of oligoden-
droglia (81, 82). Clinical symptoms include ataxia and lower 
limb paralysis that start 1 week after infection and peak 2–3 weeks 
later. After peak disease, low-level inflammation and demyelinat-
ing lesions are present, and this is likely due to viral persistence 
below the level of detection.
Studies using immunodeficient RAG1−/− mice (lacking 
functional T and B lymphocytes) have indicated that CD4+ and 
CD8+ T lymphocytes as well as macrophages are key contribu-
tors to demyelination in JHMV-infected mice (82, 83). However, 
JHMV-infected RAG1−/− mice exhibit a significant increase in 
SMI32 immunolabeling in comparison to naïve mice despite a 
lack of demyelination (83). SMI32 reactivity coincides with areas 
of macrophage and microglial infiltration and activation. There 
is a further significant increase in SMI32 immunolabeling when 
JHMV-infected RAG1−/− mice receive splenocytes from JHMV-
immunized wild-type C57Bl/6 mice, though there was no statisti-
cal difference after adoptive transfer with splenocytes depleted of 
CD4+ and CD8+ T cells. These data suggest that demyelination 
is not necessary for axonal damage to occur in JHMV-infected 
mice in that damage may be mediated by factors that can traverse 
the myelin sheath, but T cell inflammation and demyelination 
significantly exacerbate axon damage. Thus, both the inside-out 
and outside-in models of axon degeneration are perpetuated in 
JHMV according to these studies (82, 83).
Local administration of glutamate or nitric oxide donors 
induce axonopathy in mice and have also been used to under-
stand mechanisms of axonal degeneration and regeneration in 
the context of demyelinating disease (57, 84). Thus, autoimmune, 
viral, and excitoxicity-inducing models have all provided clues 
into how axonal damage may precede demyelination. However, 
an understanding of real-time interactions and visualization 
of cause-and-effect cannot be fully realized in static snapshots. 
While histopathology, flow cytometry, and molecular biology 
techniques have provided important data regarding axon biology 
in the CNS during demyelinating disease, this has largely focused 
on markers of axon damage and the presence of various inflam-
matory cells and glia. We, along with others, have employed 2P 
imaging to better understand the dynamic changes in axonal 
morphology and pathology in models of neuroinflammation, 
excitotoxicity, and cell replacement therapies.
2P imaging and Setup for Murine  
MS Models
In confocal microscopy, a single photon excites a fluorescent mol-
ecule to a higher energy state. In 2P imaging, two lower energy 
photons simultaneously excite a fluorescent molecule to a higher 
energy state. In order to achieve a high enough photon density 
for simultaneous absorption, spatial and temporal restriction is 
imposed. A high power laser is focused in pulses: during the peak 
of these pulses, there is enough energy to create 2P excitation. In 
order to create an image, the focused laser scans over the target 
tissue and the spatial photon density drops rapidly above and 
below the focus, preventing out-of-focus excitation, ultimately 
preventing background and photobleaching of surrounding 
areas. Therefore, background signal is significantly decreased 
in 2P microscopy compared to one-photon confocal micros-
copy. Furthermore, the longer excitation wavelength results in 
decreased scattering, auto-fluorescence, and phototoxicity. Due 
to this decreased scattering, 2P microscopy ideally allows imag-
ing up to 1 mm in depth, while confocal microscopy is limited to 
200 μm. As a result, this technology may be utilized to visualize 
thicker tissue sections, tissues in vivo, and whole organs in situ. 
Therefore, 2P imaging provides the ability to monitor cellular and 
molecular movement, velocity, location, and interactions within 
the endogenous CNS.
2P microscopy has been used to image axons in the brainstem, 
dorsal spinal cord, and ventral spinal cord of murine MS models. 
While the brainstem and dorsal spinal cord may be accessed 
in vivo, due to limited imaging depth, it is necessary to extract the 
spinal cord and image it in situ to capture dynamics in the ventral 
region. Therefore, in order to capture exogenously engrafted GFP-
expressing neural precursor cell (NPC) dynamics in the ventral 
spinal cord, Greenberg et al. (53) developed a novel technique to 
extract and image the spinal cord in situ. After sacrifice (omit-
ting cervical dislocation), a full laminectomy is performed from 
cervical vertebra 1 through the lumbar spinal column. The spinal 
cord is carefully resected at the necessary levels and removed. The 
spinal cords are then embedded in agarose to maintain stability 
during imaging and perfusion with warmed, oxygenated media.
Standard setup in in vivo imaging of the brainstem or spinal 
cords involves anesthetization, maintenance of body tempera-
ture, tracheotomy or intubation, maintenance of respiration, and 
circulation of saline solution or mouse artificial cerebrospinal 
fluid at the exposed imaging site. In order to expose the brain-
stem, it is necessary to incline the head to enhance imaging depth 
and remove the musculature and dura mater between cervical 
vertebra 1 and the base of the skull. A sterile agarose patch must 
be kept here to dampen breathing and heartbeat artifacts. This 
technique allows visualization of the dorsal medulla oblongata, 
caudal cerebellum, and upper spinal cord, and has been adapted 
from Gobel and Helmchen (85). In order to visualize the dorsal 
spinal cord, it is necessary to perform a laminectomy and remove 
the dura mater at the appropriate spinal cord levels, a technique 
first described by Kerschensteiner et al. (81) in 2005.
Transgenic Animal Lines
Transgenic murine lines have facilitated the use of 2P to study 
axonal degeneration in preclinical MS models. Morphology, loca-
tion, motility, concentration, and interactions of endogenously 
labeled cells, organelles, and/or various molecules can be moni-
tored during different disease states. One of the most widely used 
transgenic animal line for the study of axonopathy in preclinical 
MS models is the Thy1-XFP mouse. Thy1-XFP mice express a 
spectral variant of GFP within the cytoplasm of a subset of 
neurons (86). Axonopathy in EAE and JHMV is most commonly 
studied in the brainstem or spinal cord of Thy1-YFP or Thy1-GFP 
mice, where a large number of medium-to-large caliber axons 
fluoresce YFP or GFP, respectively. Thy1-CFP mice have been used 
to a lesser extent, due to sparser axonal fluorescence. Thy1-XFP 
mice have been crossed with CD2-GFP20 or Cx3cr1GFP/+ mice to 
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visualize T lymphocytes or macrophages/microglia, respectively, 
and their interactions with axons in active EAE (54).
Thy1-XFP mice have also been crossed with Thy1-MitoCFP 
or Thy1-PeroxiYFP mice, in order to visualize mitochondria or 
peroxisomes, respectively, within axons (54, 57). Thy1-EB3-YFP 
mice have been developed to investigate the axonal transport 
changes that occur during degeneration. Microtubules maintain 
axonal structure and directional transport within axons. End-
binding protein 3 (EB3) is one of three microtubule plus-end 
tracking proteins that facilitate microtubule growth at their grow-
ing ends (87). EB3 expresses YFP in a subset of axons in Thy1-
YFP-EB3 mice. These fluorescent EB3s resemble comets, and the 
speed, directional orientation, and length of these comet-like 
EB3 structures can be monitored as an indicator of microtubule 
outgrowth changes during pathology (57).
Recently, Förster resonance energy transfer (FRET)-based 
genetically encoded Ca2+ sensors (GECIs) have been used to 
measure [Ca2+] within neurons during pathology in preclinical 
MS models (55, 56). Thy1-TN-XXL and Thy1-CerTN-L15 trans-
genic mice express Troponin C, bound to CFP on one end and 
YFP on the other (88, 89) Troponin C is a Ca2+ binding protein 
that exhibits an expanded conformation during baseline levels 
of intracellular [Ca2+]. In this state, excitation at the absorbance 
wavelength of CFP results in CFP emission. Upon an increase in 
intracellular [Ca2+], Troponin C binds Ca2+ and contracts, bring-
ing CFP and YFP closer to each other. During excitation at the 
CFP absorbance wavelength, energy transfers from CFP to YFP 
due to their proximity, and YFP signal is emitted. Thus, changes 
in axonal [Ca2+] can be monitored by calculating the ratio of CFP 
and YFP.
Cellular and Molecular Labeling
A variety of techniques enable visualization of cellular and 
molecular activity in murine MS models aside from the use of 
transgenic animals. Tissues can be stained in  vivo, fluorescent 
cells can be transplanted from transgenic animals, and cells can 
be labeled in vitro and subsequently transplanted. The former two 
techniques have been utilized in the study of axonal pathology in 
murine MS models. Romanelli et al. (86) published a protocol for 
staining spinal cord tissue in vivo for 2P imaging. This protocol has 
been used to label myelin using FluoroMyelin stain (Invitrogen), 
Cell Trace BODIPY TR methyl ester dye (Invitrogen), or Nile red 
stain and inflammatory cellular infiltrates in Thy1-XFP animals 
(54, 56). Vital dyes have also been used with 2P imaging to visual-
ize real-time changes in relevant molecular concentrations or sig-
nals, such as hydrogen peroxide (ROS), measured with AMPLEX 
UltraRed reagent (Invitrogen); nitric oxide (RNS), measured 
with DAF-FM diacetate reagent (Invitrogen); and mitochondrial 
membrane potential, measured with tetramethylrhodhamine 
(TMRM), methyl ester (Invitrogen) (54).
Siffrin et al. (56) created bone marrow chimeric mice in order 
to visualize the activity of RFP-expressing bone marrow-derived 
peripheral immune cells (CD45+) in Thy1-EGFP (tdRFP → Thy1-
EGFP) animals in which EAE was induced. This group also initi-
ated EAE in Rag1−/− × Thy1-EGFP mice by injection of in vitro 
differentiated MOG35–55-specific TCR transgenic (2d2) Th17 cells 
from tdRFP mice (2d2.tdRFP Th17). T helper cells were isolated 
from total splenocytes using CD4+CD62L+ magnetic bead cell 
sorting. These cells were then stimulated with MOG peptide and 
cytokines to induce specificity and differentiation into Th17 cells. 
These cells were also transplanted into RAG1−/− × Thy1-EGFP ani-
mals following induction of EAE via injection of  non-fluorescent 
2d2 Th17 cells, allowing visualization of RFP-expressing Th17 
cells in relation to EGFP axons. IL-17A-enriched 2d2.tdRFP 
Th17, 2d2.tdRFP Th1, and ovalbumin-specific TCR transgenic 
Th17 (OT-2.tdRFP Th17) cells, which were derived in a similar 
manner in  vitro, were also visualized after transplantation into 
non-fluorescent 2d2 Th17-induced EAE RAG1−/− × Thy1-EGFP 
animals. As a result, it was possible to monitor dynamics and 
interactions of Th1 and Th17 cells with varied differentiation 
status and specificity in relation to EAE-induced axonopathy.
Our laboratory has used NPCs derived from GFP (GFP–NPCs) 
and PLP–GFP (PLP–GFP–NPCs) mice; these cells express GFP 
constitutively or under control of the proteolipid protein (PLP) 
promoter, respectively (53). Through the use of 2P microscopy 
to monitor live interactions, we verified previous histologic 
evidence of NPC differentiation upon interaction with damaged 
axons in JHMV-infected Thy1-YFP mice. Thus, a large variety of 
experiments can be conducted with selected transgenic mouse 
lines in combination with 2P imaging. With the addition of vital 
dyes, which do not require the time and expense of animal care, 
the number of variables that can be simultaneously monitored 
dramatically expands.
Technical Considerations
Some technical limitations must be considered when using 2P 
microscopy. Photobleaching must be mitigated by using a low 
laser power. Compensatory equations, such as a monoexponen-
tial decay adjustment have been utilized to normalize for this 
phenomenon (55). Variance in scattering by different fluoro-
phores may give false impression of relative emission intensity 
with depth. Ratiometric signaling constructs, such as those used 
in GECIs, may be affected by this. Since CFP scatters more than 
YFP, the YFP/CFP ratio of axons within the brainstems of Thy1.
CerTN-L15 or Thy1-TN-XXL mice will increase with depth, giv-
ing a false impression of slight [Ca2+] increase (55, 56). A linear 
correction may be useful in compensating for the differential 
scattering.
Considering the depth limitation of 2P microscopy, alterna-
tive methods may aid in gaining a complete understanding of 
pathology in the CNS. MRI may be utilized to identify deep 
lesions of inflammation, axonal damage, and demyelination 
in live mice (90–92). Following lesion identification, it may be 
possible to take tissue sections of deep lesions and visualize live 
cellular and molecular dynamics in  situ using 2P microscopy 
(93). Alternatively, a variety of techniques have been developed 
in order to make tissue sections and whole organs transparent 
(94–96). Transparentization reduces scattering and allows greater 
imaging depth with both 2P and confocal microscopy. However, 
this process requires fixation; thus, it can only be used to visualize 
a static snapshot of pathology.
Vital dyes may exhibit non-specific binding, compartmentali-
zation, and leakage (97). Therefore, it is necessary to minimize 
variations in preparation of dye, location of dye administration, 
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dye incubation time, imaging duration, and location of imaging. 
While transgenic animal lines may seem superior in consideration 
of these limitations, the additional data that can be easily gained 
with these dyes makes them an irreplaceable boon to live imaging 
at this current time.
Given the variety and advancement of techniques to visualize 
cells, organelles, and various molecules, one must consider the 
limitation posed by overlap of emission spectra. Generally, a lim-
ited number of channels can be detected at a time. Furthermore, 
while many transgenic variants and vital dyes have been made, 
their emission spectra are most often GFP or RFP, and to a lesser 
extent YFP or CFP have been used. There must be enough variety 
such that each variable in an experiment has a different emission 
spectrum.
ADvANCeS iN UNDeRSTANDiNG AXONAL 
DeGeNeRATiON AND RePAiR
Axon Morphologic Changes
Using time-lapse 2P imaging to look at axons in Thy1-YFP mice 
in the EAE and JHMV models, a novel temporal connection was 
made between the axonal swelling, ovoids, transections, and thin-
ning that had been described in MS and other neurodegenerative 
diseases (53, 54). In 2011, Nikic et al. (54) described the reversible 
and progressive stages of axonal pathologies observed with 2P 
microscopy in EAE mice post-onset, termed focal axonal degen-
eration (FAD). FAD consists of three stages: stage 0 is a normal 
appearing axon, a stage 1 axons has focal swellings, and a stage 
2 axon has transections. Axon pathology can progress or reverse 
through these stages. Stage 1 axons may progress to stage 2 or 
regress to stage 0. Importantly, stage 2 axons were not observed 
to revert back to stage 0.
Using a 2P approach, we observed that FAD also occurs in 
JHMV-infected Thy1-YFP mice early following CNS infection 
(Figure 2A) (53). Upon further immunolabeling with SMI32, we 
detected additional nuances to the FAD pathologies previously 
described. Axons could have any combination of YFP+SMI32−, 
YFP−SMI32+, YFP+SMI32+, and/or YFP−SMI32− sections: this 
means that parts of axons could be considered healthy and 
intact, intact but damaged, or transected (Figure  2B). The 
detection of YFP−SMI32+ axons indicated that YFP loss may 
not be sufficient to indicate complete transection. Subsequent 
immunolabeling with SMI31 to detect “healthy” phosphoryl-
ated neurofilament showed that SMI31 immunoreactivity was 
exclusive to YFP+ axons.
These data also contributed to a historically important ques-
tion regarding axonal degeneration in demyelinating disease: 
all three stages were detected in myelinated axons, providing 
traction for the inside-out model of axonal degeneration. FAD 
1 and 2 axons were found in fully myelinated axons, though 
there were more partially or fully demyelinated stage 1 and 
stage 2 axons (54). This corroborates previous MS data in that 
axonal degeneration can occur in myelinated axons, but is 
more prevalent in demyelinated axons. Inflammation has been 
ubiquitously linked to axonal degeneration. Using time-lapse 
2P imaging, Nikic et al. (54) also found that stage 1 axons were 
more likely to degenerate into stage 2 axons during peak clini-
cal symptoms and elevated inflammation, while recovery was 
more likely even 1 day after peak symptoms. Using 2P imaging 
to complement standard laboratory techniques and transgenic 
animals, our understanding of the temporal characteristics of 
axonal degeneration in demyelinating disease has been cor-
roborated and advanced.
Organelle Transport and Damage
Morphologic changes in axons are accompanied by organelle 
damage and transport deficiencies (98). Though normally unde-
tectable by immunolabeling, APP is detected when it accumulates 
due to defective axonal transport. It has been found in acute 
lesions and at the borders of active chronic MS lesions (19). 2P 
imaging of spinal cords of Thy1-EB3-YFP EAE mice show that 
FAD 1 axons have a significant increase in EB3 “comets” oriented 
in the retrograde direction compared to FAD 0 axons or axons in 
control mice (57). Microtubule orientation is also highly variant. 
FiGURe 2 | (A) Representative 2P image of axons in JHMV-infected Thy1-YFP mice shows FAD stages 0, 1, and 2, 21 days post-infection (53). (B) Representative 
image of SMI32 immunohistochemistry (non-phosphorylated neurofilament) in Thy1-YFP mice, 23 days post-infection shows YFP+SMI32− sections (yellow arrow), 
YFP+SMI32+ sections (white arrow), YFP−SMI32+ sections (red arrow), and YFP−SMI32− sections (white arrowhead) (53). (Scale bar = 20 μm).
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EB3 is most often parallel to the axon; however, upon induction 
of EAE, FAD1 axons exhibited comets oriented in various angles.
In order to continue to understand transport deficiencies, 
Sorbara et  al. (57) visualized axonal mitochondria and peroxi-
somes. 2P microscopy has allowed for visualization and quanti-
fication of velocity, directionality, location, and stop duration. In 
concordance with the EB3 data, both anterograde and retrograde 
mitochondrial flux is significantly decreased in FAD1 axons (57). 
Furthermore, both mitochondrial and peroxisomal flux is signifi-
cantly decreased in FAD 0 EAE axons compared to control axons, 
indicating that transport deficits may occur before morphological 
changes to axons. Mitochondrial speed is significantly decreased, 
stop duration is significantly increased, and the frequency of 
stops is significantly increased in the anterograde direction in 
EAE axons. As a result of these mitochondrial transport deficits, 
a significant reduction was seen in organelle density in distal 
portions of axons, matching the increase in retrograde-oriented 
EB3. The lack of organelles, such as mitochondria, throughout 
the length of axons may have significant impact on maintaining 
neuronal homeostasis and health.
Tracking mitochondria to monitor transport deficiencies in 
MS models is highly useful, considering that it has also been 
identified as an early marker of axonal pathologies. Cortical 
biopsies of MS patients have shown decreased mRNA expres-
sion and impaired activity of mitochondrial electron transport 
chain complexes (50–52). These effects may be correlated with 
inflammation in that a decrease in axonal mitochondria complex 
IV activity was associated with an increase in local macrophage/
microglial density (52). These findings corroborate the complex 
interaction of inflammation, axonal health, and mitochondrial 
health and density.
Deficient transport of mitochondria throughout axons is com-
plemented by mitochondrial structural and functional changes. 
Parallel to evidence that mitochondria transport deficits occur 
in “normal” FAD 0 axons, mitochondrial dysfunction and dys-
morphia precede morphologic changes of axons (54). Electron 
microscopy revealed swollen, rounded mitochondria within FAD 
1 axons of EAE-induced mice. Given this information, EAE was 
induced in Thy1-YFP-16 × Thy1-MitoCFP mice for visualization 
of mitochondrial morphology and membrane potential with 2P 
imaging. Quantification of these factors revealed that decreased 
shape factor (indicating dysmorphia) correlated with abnormally 
low mitochondrial membrane potential. While dysmorphic mito-
chondria were not found in either control animals or MOG35–55 
immunized animals prior to disease onset, swollen mitochondria 
were found in FAD 0 axons located within inflammatory lesions. 
In concordance with previous histologic MS data, axonal mito-
chondria damage was localized to areas of increased macrophage 
and microglial inflammation, perhaps due to release of ROS and 
RNS (17, 25, 49–52).
Reactive oxygen species and RNS were significantly increased 
in lesions of EAE mice upon onset (54). Application of these spe-
cies to healthy Thy1-YFP-16 × Thy1-MitoCFP mice spinal cord 
showed that both result in mitochondrial and FAD changes, similar 
to what occurs in EAE, but without demyelination. Examination 
of active lesions from MS biopsies showed  mitochondrial  damage 
regardless of demyelination state, similar to data showing fully 
myelinated FAD 1 and 2 axons (54). Therefore, 2P imaging 
provides significant evidence that axonal damage and related 
transport and mitochondrial deficiencies occur in areas of inflam-
mation, and release of ROS and RNS species by macrophages and 
microglia may be one contributor of axonal damage.
inflammation and Axon Health
Inflammatory cells have been found to contact axons and cause 
degeneration in demyelinating disease. SMI32 reactive axons 
were found in areas with high macrophage and microglial 
density in JHMV spinal cord (83). In MS, APP reactive axons 
increased in a correlative manner with CD8+ T lymphocyte and 
macrophage/microglia density in lesions and periplaque white 
matter (24). Furthermore, the pattern of axonal transections 
in active and chronic active lesions matched that of MHC class 
II-positive macrophages and microglia (18). Apposition, contact, 
and engulfment of axons, dendrites, and soma by microglia 
have been detected in MS active and chronic active cortical 
lesions, and correlate with axonal damage and transection (17). 
Using 2P microscopy, Nikic et al. (54) also found an increase in 
macrophage and microglial density local to axons in acute EAE 
lesions in Cx3cr1GFP/+ × Thy1-CFP-S mice.
Siffrin et  al. (56) used 2P microscopy in the brainstems of 
EAE mice to understand the motility characteristics of Th17 cells, 
which have been implicated in causing clinical and histologic 
disease upon induction of EAE. CD45+ cells in MOG35–55-induced 
active EAE in bone marrow chimera tdRFP → Thy1.EGFP mice 
and adoptively transferred in vitro differentiated 2d2.tdRFP Th17 
cells for passive induction of EAE in RAG1−/− × Thy1-EGFP mice 
both showed high motility and invasiveness into the parenchyma. 
However, 2d2.tdRFP Th17 cells showed decreased velocity during 
peak and chronic disease, while CD45+ cells maintained their 
velocity through all disease stages with the exception of remis-
sion. This decrease in velocity was associated with decreased 
displacement rate and increased meandering during disease. This 
corroborates the notion that antigen-specific T cells stop upon 
recognition of cognate antigen presented by MHC molecules as 
previously shown in EAE (99–101).
Consequently, Siffrin et  al. (56) induced passive EAE 
in RAG1−/−  ×  Thy1-EGFP mice by adoptive transfer of 
 non-fluorescent 2d2 Th17 cells to visualize the effects of differen-
tiation status and antigen-specificity on interactive behavior. This 
study compared 2d2.tdRFP Th17, IL-17A enriched 2d2.tdRFP 
Th17, OT-2.tdRFP Th17, and 2d2.tdRFP Th1 cells. All three Th17 
cell types had higher mean velocities and displacement rates than 
Th1 cells. Further analysis showed that the Th17 cells increasingly 
scanned dysmorphic axons in lesions: they contacted neurons 
more frequently and longer, particularly at peak disease. On the 
other hand, Th1 cells did not seem to undergo motility changes 
akin to antigen recognition, rather engaging in random, non-
specific, and abbreviated contacts.
However, these data also indicate that Th17-neuronal contact 
is antigen independent as both 2d2.tdRFP and OT-2.tdRFP Th17 
cells engaged in these neuronal interactions. Using electron 
microscopy and in vitro co-cultures with immunocytochemistry 
to further characterize these interactions, Siffrin et al. (56) found 
contacts between T lymphocytes and various myelinated and 
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unmyelinated regions of neurons. At the point of contact, T lym-
phocytes exhibited polarization of organelles and microtubule-
organizing centers, similar to immune synapses. These contacts 
were found to be MHC class II and antigen independent, but 
dependent on adhesion molecule LFA-1, which clusters at 
immune synapse contact sites and targets cytolytic granules to 
the cell surface (102). While Th17 cells caused neuronal death in 
co-cultures, Th0 and Th1 cells, and Th17 supernatants did not. 
These data imply that Th17 cells make an immune synapse-like 
contact with neurons, especially during peak disease, potentially 
causing neuronal degeneration and death. The discovery of this 
remarkable interaction was highly dependent on the ability to 
visualize these interactions in real time.
Neuronal excitotoxicity
Sustained Th17-neuronal contacts in EAE correlated with 
intracellular [Ca2+] increase, an early sign of axonal pathology 
(38, 103). Increased axon [Ca2+] was seen upon CD45+ cell con-
tact, which decreased upon separation in MOG-EAE-induced 
bone marrow chimeric tdRFP→Thy1.Tn-XXL mice (55). 
Thy1.CernL15 animals induced with passive EAE by adoptive 
transfer of 2d2.tdRFP Th17 cells into RAG1−/− × Thy1-CernL15 
or induced with active MOG-EAE in tdRFP→Thy1.CernL15, 
showed localized [Ca2+] increase within contacting neuronal 
processes and soma in EAE lesions (56). The highest [Ca2+] 
increase in the Thy1.CernL15 model was found at the borders 
of active demyelinating lesions, which had a high amount of 
disintegrating myelin and debris. Sustained contact resulted 
in achievement of critical [Ca2+] signal, which preceded axon 
dissection at contact site and irreversible damage in soma. When 
quantifying GFP voxels as an indicator of neurodegeneration, 
decreased neuronal tissue was found in the presence of 2d2 Th17 
cells; increased APP immunolabeling corroborated these results. 
Indeed, 2d2 Th17 caused a more progressive disease, with 
decreased remissions and increased mortality compared to 2d2 
Th1 cells. Interestingly, injection of ovalbumin-specific CD4+ 
T cells resulted in reduced [Ca2+] elevation in axons. Though 
velocity and contacting dynamics were not found to be antigen 
specific, axonal [Ca2+] changes may be.
Glutamate excitotoxicity also causes an increase in axonal 
[Ca2+] (38, 39). Inhibition of NMDA glutamate receptors in 
EAE has shown decreased neurologic symptoms and inflam-
matory cytokine production (104–107). 2P imaging showed 
that local administration of glutamate to the brainstem of 
Thy1.TN-XXL mice resulted in local axonal [Ca2+] increases 
as well as morphologic changes, such as swelling and transec-
tions. These data indicate the variety of changes occurring in 
axons in preclinical MS models and the wide array of potential 
therapeutic targets, including glutamate excitotoxicity, mor-
phologic changes, ion concentration changes, and inflamma-
tory cell contact.
Regenerative Therapeutics and Neural 
Precursor Cells
Drugs/molecular therapeutics and NPCs have been investigated 
for their potential to alleviate axonal pathologies in MS models. 
The molecular therapeutics tested are FDA-approved MS drugs, 
their biological byproducts, axonal channel/receptor blockers, 
and ROS/RNS scavengers. These therapeutics and their effects 
on axonal pathology as monitored by 2P microscopy are sum-
marized in Table 1.
The allure of stem cells lies in their ability to differentiate 
and replace lost tissue as well as their release of regenerative 
factors. The therapeutic potential of neural stem cells (NSCs) 
and NPCs has been investigated in demyelinating disease, espe-
cially in regard to their ability to myelinate axons. Numerous 
transplantation studies in demyelinating models, such as EAE 
and shiverer mice, a genetic model of dysmyelination, have 
shown that NSC/NPC-based therapy decreases inflammation 
and increases the number of myelinating cells in the CNS 
(108–111). These therapies include bone marrow mesenchymal 
stem cell-derived NSCs, oligodendrocyte progenitor cells, and 
human CNS NSCs. Transplantation of allogeneic human CNS 
stem cells into the frontal lobe of human patients with early 
TABLe 1 | Molecular therapeutics for axonal regeneration and results of 2P imaging.
Therapeutic Disease model 2P imaging results Reference
FTY720, FTY720-P, MMF, or DMF (MS drugs 
and analogs)
Glutamate delivery Delayed [Ca2+] increase or decreased [Ca2+]; slower or decreased FAD Luchtman et al. (84)
MK-801 (NMDAR blocker) Glutamate delivery Prevention of FAD Luchtman et al. (84)
MK-801 (NMDAR blocker) EAE Intracellular [Ca2+] reduction to baseline in Th17 contacting axons Siffrin et al. (56)
PHT (Na+ channel blocker) EAE Intracellular [Ca2+] reduction in Th17 contacting axons, less than 
MK-801
Siffrin et al. (56)
FeTPPs, PBN, and EUK134 (ROS and RNS 
scavenger cocktail)
EAE Recovery of FAD 1 axons Nikic et al. (54)
cPTIO (RNS scavenger) Spermine (RNS donor) 
delivery
Rescue of mitochondrial velocity (anterograde and retrograde) Sorbara et al. (57)
Methylprednisolone (Corticosteroid) EAE Rescue of mitochondrial velocity (anterograde and retrograde) Sorbara et al. (57)
FeTPPs, PBN, and EUK134 (ROS and RNS 
scavenger cocktail)
EAE Rescue of mitochondrial velocity (anterograde and retrograde) Sorbara et al. (57)
FTY720, Fingolimod; FTY720-P, FTY720-phophate; DMF, dimethyl fumarate; MMF, monomethyl fumarate; PHT, phenytoin; FeTTPS, 5,10,15,20-Tetrakis(4-sulfonatophenyl)
porphyrinato Iron (III), chloride; PBN, N-tert-butyl-α-phenylnitrone; cPTIO, 2-4-carboxyphenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide.
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FiGURe 3 | 2P imaging of (A) healthy and (B) degenerating axons in 
preclinical MS models has shown that many factors are involved in 
axonopathy and many features can be assayed as indicators of 
axonal degeneration. Activated macrophages and microglia (M) release 
glutamate, ROS, and RNS in the pathogenic environment and these factors 
contribute to morphological degeneration of the axon (FAD), disorientation of 
EB3 (indicative of microtubule-based transport), dysmorphia of mitochondria, 
and increased intracellular [Ca2+]. Intracellular [Ca2+] is also locally increased 
during Th17 cell contact in EAE. Organelles, such as mitochondria, are 
absent in the distal parts of damaged axons. Thus, inflammation is implicated 
in axonopathy in preclinical MS models.
onset Pelizaeus–Merzbacher disease, a congenital dysmyelinat-
ing disease, indicated that the procedure was safe and well 
tolerated, and also resulted in myelination (109). These results 
are promising and require further investigation to understand 
mechanism of action. 2P microscopy is a well-suited technique 
to monitor dynamic interactions between these therapeutic 
cells and damaged axons in animal models.
Electron microscopy and immunohistochemistry implied 
that syngeneic murine NPCs transplanted into JHMV-infected 
mice remyelinated axons, and 2P imaging in Thy1-YFP mice 
confirmed this initial observation (112). Transplanted GFP–
NPCs preferentially localized to axons with increasing FAD; 
engraftment of PLP–GFP–NPCs confirmed that NPCs mature 
into myelin-producing oligodendrocytes and remyelinated 
axons (53). Immunostaining of transverse spinal cord sections 
of PLP–GFP–NPC transplanted JHMV-infected Thy1-YFP 
mice for myelin basic protein (MBP), another component of 
myelin, showed that these cells were indeed producing myelin. 2P 
microscopy allowed for live visualization of spatial juxtaposition 
of therapeutic NPCs with axons for the first time. A summary of 
the cellular and molecular components of axonopathy that have 
been imaged with 2P microscopy in preclinical MS models can 
be found in Figure 3.
CONCLUSiON AND FUTURe 
PeRSPeCTiveS
Our perspective is that 2P microscopy is currently the highest 
resolution methodology for live imaging normal and diseased 
CNS tissue. A number of advancements make this technology 
accessible for imaging axonopathy, such as the development of 
CNS imaging setups, transgenic animals for visualization of axons 
in the CNS, and various chemicals and dyes to visualize other 
structures. Thus far, 2P microscopy has facilitated significant 
gains in understanding axonal degeneration in murine MS mod-
els. EAE has been known to be Th17 dependent for some time; 
with the use of 2P and transgenic Ca2+ reporter mice, a unique 
and novel connection has been made between Th17 cells, FAD, 
and irreversible neuronal damage. Similarly, while morphological 
damage to axons has been detected with stains for neurofilament, 
such as SMI31, SMI32, and Bielschowsky silver impregnation, 
discovery of the temporal progression in morphological damage 
was made possible by time-lapse 2P imaging.
Despite this significant progress, whether demyelination or 
axonal damage occurs first has not been sufficiently answered. 
2P data show that structural degeneration, mitochondrial impair-
ment, and ion concentration imbalance may start to occur before 
demyelination. However, some of these axonal pathologies are 
products of inflammation, and demyelination is too. But FDA-
approved disease-modifying therapies and corticosteroids, which 
are believed to reduce neuroinflammation, are not believed to 
prevent onset of progressive disease. Therefore, it may be possible 
that alternate mechanisms are causing axonal damage, or current 
therapeutics do not sufficiently decrease neuroinflammation. 
While the data increasingly suggests the verity of the inside-out 
model and the possibility that axon damage and demyelination 
are independent events, their cause may be the same. Continued 
study of these phenomena is necessary to develop potential 
therapies.
More research is required to answer the following questions 
about axonal damage in MS: does axonopathy or demyelination 
occur first, is a single-target therapeutic sufficient for alleviation 
of axonopathy, can NSCs/NPCs provide long-term treatment 
for demyelinating disease? 2P imaging has provided significant 
gains in moving closer to answering these questions. Thus far, 
the relationships between ROS, RNS, glutamate, inflammation, 
and axonal pathologies, such as morphologic damage, transport 
deficits, mitochondrial deficiencies, and [Ca2+] excitotoxicity, 
have been investigated using 2P. Important areas of study in 
the future will be mechanism of demyelination onset in viral 
models, cause and effect of glutamate excitotoxicity, and loss 
of trophic support by glia and downstream neurons. These are 
a few of many. Ultimately, by better understanding the complex 
relationships occurring in neuroinflammatory demyelination, 
we may stumble upon a single point of convalescence. One of 
the challenges of developing therapeutics for MS is a lack of 
understanding about pathogenesis. Together, preclinical murine 
models and 2P microscopy provide a methodology to understand 
onset of demyelination and axonopathy. Thus, 2P microscopy 
may facilitate in gaining a mechanistic understanding of axonal 
damage in order to develop therapeutics for progressive MS.
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